CDKN2B-AS1 and melanoma: This fusion gene, documented to exhibit a frequency exceeding 7% in melanoma, results from a chromosomal rearrangement between ANRIL and MTAP, a tumor suppressor gene involved in purine metabolism (methylthioadenosine phosphorylase) [139].